NCT02922426View on ClinicalTrials.gov

An Insulin Sensitivity Study in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

July 20, 2017

Study Completion Date

July 20, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

ALKS 3831

Daily dosing for 21 consecutive days

DRUG

Olanzapine

Daily dosing for 21 consecutive days

DRUG

Placebo

Daily dosing for 21 consecutive days

Trial Locations (1)

91911

Alkermes Investigational Site, Chula Vista

Sponsors

Lead Sponsor

Alkermes, Inc.
All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY